Cellectis Total Liabilities
Cellectis total liabilities. Based on the latest financial reports, Cellectis (ALCLS) has total liabilities worth €226.30 Million EUR (≈ $264.57 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Cellectis to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cellectis (2002–2025)
Total liabilities of Cellectis from 2002 to 2025. This chart illustrates how Cellectis's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Cellectis's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cellectis Competitors by Total Liabilities
The table below lists competitors of Cellectis ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rithm Property Trust Inc.
NYSE:RPT
|
USA | $643.90 Million |
|
Chateau International Development Co Ltd
TW:2722
|
Taiwan | NT$1.09 Billion |
|
Sao Ta Foods JSC
VN:FMC
|
Vietnam | ₫1.79 Trillion |
|
Right Way Industrial Co Ltd
TW:1506
|
Taiwan | NT$426.92 Million |
|
Gigante Salmon AS
OL:GIGA
|
Norway | Nkr610.38 Million |
|
Téléverbier SA
PA:TVRB
|
France | €97.96 Million |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
India | Rs4.69 Billion |
|
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.)
NASDAQ:LION
|
USA | $6.32 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Cellectis's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALCLS total assets.
Liquidity & Leverage Metrics
Cellectis Total Liabilities Ratios Explained
Cellectis total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis (2002–2025)
The table below shows the annual total liabilities of Cellectis from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €248.85 Million ≈ $290.93 Million |
-1.45% |
| 2024-12-31 | €252.51 Million ≈ $295.21 Million |
+1.18% |
| 2023-12-31 | €249.57 Million ≈ $291.78 Million |
+84.49% |
| 2022-12-31 | €135.28 Million ≈ $158.15 Million |
-7.09% |
| 2021-12-31 | €145.60 Million ≈ $170.22 Million |
-9.35% |
| 2020-12-31 | €160.62 Million ≈ $187.79 Million |
+43.42% |
| 2019-12-31 | €112.00 Million ≈ $130.94 Million |
+121.48% |
| 2018-12-31 | €50.57 Million ≈ $59.12 Million |
+7.64% |
| 2017-12-31 | €46.98 Million ≈ $54.92 Million |
-17.05% |
| 2016-12-31 | €56.63 Million ≈ $66.21 Million |
-33.11% |
| 2015-12-31 | €84.67 Million ≈ $98.99 Million |
-10.83% |
| 2014-12-31 | €94.95 Million ≈ $111.01 Million |
+153.46% |
| 2013-12-31 | €37.46 Million ≈ $43.80 Million |
+12.10% |
| 2012-12-31 | €33.42 Million ≈ $39.07 Million |
-64.77% |
| 2011-12-31 | €94.86 Million ≈ $110.91 Million |
+396.58% |
| 2010-12-31 | €19.10 Million ≈ $22.33 Million |
+5.44% |
| 2009-12-31 | €18.12 Million ≈ $21.18 Million |
+23.92% |
| 2008-12-31 | €14.62 Million ≈ $17.09 Million |
+41.54% |
| 2007-12-31 | €10.33 Million ≈ $12.08 Million |
+99.77% |
| 2006-12-31 | €5.17 Million ≈ $6.05 Million |
+21.87% |
| 2005-12-31 | €4.24 Million ≈ $4.96 Million |
+144.84% |
| 2004-12-31 | €1.73 Million ≈ $2.03 Million |
+37.76% |
| 2003-12-31 | €1.26 Million ≈ $1.47 Million |
-3.16% |
| 2002-12-31 | €1.30 Million ≈ $1.52 Million |
-- |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more